FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048845916> ?p ?o ?g. }

• W3048845916 endingPage "2092.e10" @default.
• W3048845916 startingPage "2082" @default.
• W3048845916 abstract "Background & Aims Ustekinumab is a monoclonal antibody against interleukin 12 and interleukin 23 that has been approved by the Food and Drug Administration for treatment of Crohn’s disease (CD). We sought to identify the ideal position for ustekinumab in treatment algorithms for CD. Methods We constructed a Markov model to identify an optimal treatment sequence for CD that included ustekinumab for 1 year or more. The base case was a 35-year old male with moderate to severe CD who had not previously received biologic or immunomodulator therapy. The standard of care treatment algorithm was defined as initial therapy with infliximab and azathioprine, followed by adalimumab and azathioprine, vedolizumab, and lastly surgical resection. The model assessed positions for ustekinumab before standard of care, ustekinumab after infliximab and azathioprine but before the remaining treatments, after infliximab, azathioprine, and adalimumab but before vedolizumab and surgery, or after the other biologics but before surgery. We derived transition probabilities and quality adjusted life years (QALYs) from relevant trials, observational studies, and time trade-off analyses. Primary analyses consisted of first order Monte Carlo simulation of 100 trials of cohorts of 100,000 individuals. Results Ustekinumab as first-line therapy yielded the greatest QALYs (incremental effectiveness, 0.016–0.020 QALYs), resulting in 10% more patients in remission or response, and 2% fewer surgeries at 1 year, compared with other algorithms. The model was not sensitive to 25% variation in transition probabilities. Conclusions In a simulation based on a 35-year old male patient with moderate to severe CD, we found that ustekinumab as the first-line biologic therapy yields greater QALYs at the end of 1 year than compared with use later in the CD treatment algorithm. Ustekinumab is a monoclonal antibody against interleukin 12 and interleukin 23 that has been approved by the Food and Drug Administration for treatment of Crohn’s disease (CD). We sought to identify the ideal position for ustekinumab in treatment algorithms for CD. We constructed a Markov model to identify an optimal treatment sequence for CD that included ustekinumab for 1 year or more. The base case was a 35-year old male with moderate to severe CD who had not previously received biologic or immunomodulator therapy. The standard of care treatment algorithm was defined as initial therapy with infliximab and azathioprine, followed by adalimumab and azathioprine, vedolizumab, and lastly surgical resection. The model assessed positions for ustekinumab before standard of care, ustekinumab after infliximab and azathioprine but before the remaining treatments, after infliximab, azathioprine, and adalimumab but before vedolizumab and surgery, or after the other biologics but before surgery. We derived transition probabilities and quality adjusted life years (QALYs) from relevant trials, observational studies, and time trade-off analyses. Primary analyses consisted of first order Monte Carlo simulation of 100 trials of cohorts of 100,000 individuals. Ustekinumab as first-line therapy yielded the greatest QALYs (incremental effectiveness, 0.016–0.020 QALYs), resulting in 10% more patients in remission or response, and 2% fewer surgeries at 1 year, compared with other algorithms. The model was not sensitive to 25% variation in transition probabilities. In a simulation based on a 35-year old male patient with moderate to severe CD, we found that ustekinumab as the first-line biologic therapy yields greater QALYs at the end of 1 year than compared with use later in the CD treatment algorithm." @default.
• W3048845916 created "2020-08-18" @default.
• W3048845916 creator A5013639104 @default.
• W3048845916 creator A5041936168 @default.
• W3048845916 creator A5050314988 @default.
• W3048845916 creator A5055266545 @default.
• W3048845916 creator A5056339603 @default.
• W3048845916 creator A5067719692 @default.
• W3048845916 creator A5087788844 @default.
• W3048845916 date "2021-10-01" @default.
• W3048845916 modified "2023-09-30" @default.
• W3048845916 title "Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn’s Disease" @default.
• W3048845916 cites W1661616496 @default.
• W3048845916 cites W1853249566 @default.
• W3048845916 cites W1991810959 @default.
• W3048845916 cites W1996198481 @default.
• W3048845916 cites W2030086403 @default.
• W3048845916 cites W2035481305 @default.
• W3048845916 cites W2036139910 @default.
• W3048845916 cites W2075090387 @default.
• W3048845916 cites W2077531651 @default.
• W3048845916 cites W2085127303 @default.
• W3048845916 cites W2088826436 @default.
• W3048845916 cites W2100942700 @default.
• W3048845916 cites W2121609590 @default.
• W3048845916 cites W2126807394 @default.
• W3048845916 cites W2140421779 @default.
• W3048845916 cites W2152026434 @default.
• W3048845916 cites W2165765440 @default.
• W3048845916 cites W2171202562 @default.
• W3048845916 cites W2171341132 @default.
• W3048845916 cites W2321453230 @default.
• W3048845916 cites W2323880056 @default.
• W3048845916 cites W2325045814 @default.
• W3048845916 cites W2560112556 @default.
• W3048845916 cites W2593085926 @default.
• W3048845916 cites W2606904392 @default.
• W3048845916 cites W2615184173 @default.
• W3048845916 cites W2790568383 @default.
• W3048845916 cites W2794595980 @default.
• W3048845916 cites W2809001101 @default.
• W3048845916 cites W2945649262 @default.
• W3048845916 cites W2946624328 @default.
• W3048845916 cites W2948759662 @default.
• W3048845916 cites W4205253993 @default.
• W3048845916 cites W4211167126 @default.
• W3048845916 cites W4233817719 @default.
• W3048845916 cites W4236521244 @default.
• W3048845916 cites W2080550556 @default.
• W3048845916 doi "https://doi.org/10.1016/j.cgh.2020.08.021" @default.
• W3048845916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32801006" @default.
• W3048845916 hasPublicationYear "2021" @default.
• W3048845916 type Work @default.
• W3048845916 sameAs 3048845916 @default.
• W3048845916 citedByCount "4" @default.
• W3048845916 countsByYear W30488459162021 @default.
• W3048845916 countsByYear W30488459162022 @default.
• W3048845916 countsByYear W30488459162023 @default.
• W3048845916 crossrefType "journal-article" @default.
• W3048845916 hasAuthorship W3048845916A5013639104 @default.
• W3048845916 hasAuthorship W3048845916A5041936168 @default.
• W3048845916 hasAuthorship W3048845916A5050314988 @default.
• W3048845916 hasAuthorship W3048845916A5055266545 @default.
• W3048845916 hasAuthorship W3048845916A5056339603 @default.
• W3048845916 hasAuthorship W3048845916A5067719692 @default.
• W3048845916 hasAuthorship W3048845916A5087788844 @default.
• W3048845916 hasConcept C11413529 @default.
• W3048845916 hasConcept C126322002 @default.
• W3048845916 hasConcept C2776207728 @default.
• W3048845916 hasConcept C2776760755 @default.
• W3048845916 hasConcept C2777138892 @default.
• W3048845916 hasConcept C2778975655 @default.
• W3048845916 hasConcept C2779134260 @default.
• W3048845916 hasConcept C2779280984 @default.
• W3048845916 hasConcept C2780132546 @default.
• W3048845916 hasConcept C41008148 @default.
• W3048845916 hasConcept C71924100 @default.
• W3048845916 hasConceptScore W3048845916C11413529 @default.
• W3048845916 hasConceptScore W3048845916C126322002 @default.
• W3048845916 hasConceptScore W3048845916C2776207728 @default.
• W3048845916 hasConceptScore W3048845916C2776760755 @default.
• W3048845916 hasConceptScore W3048845916C2777138892 @default.
• W3048845916 hasConceptScore W3048845916C2778975655 @default.
• W3048845916 hasConceptScore W3048845916C2779134260 @default.
• W3048845916 hasConceptScore W3048845916C2779280984 @default.
• W3048845916 hasConceptScore W3048845916C2780132546 @default.
• W3048845916 hasConceptScore W3048845916C41008148 @default.
• W3048845916 hasConceptScore W3048845916C71924100 @default.
• W3048845916 hasFunder F4320337601 @default.
• W3048845916 hasIssue "10" @default.
• W3048845916 hasLocation W30488459161 @default.
• W3048845916 hasOpenAccess W3048845916 @default.
• W3048845916 hasPrimaryLocation W30488459161 @default.
• W3048845916 hasRelatedWork W2414272582 @default.
• W3048845916 hasRelatedWork W2914662974 @default.
• W3048845916 hasRelatedWork W2984488335 @default.
• W3048845916 hasRelatedWork W2989681206 @default.
• W3048845916 hasRelatedWork W2999567714 @default.

• next